Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis

Exclusion Criteria

• •1. Subject has any vaginal condition other than AVVC that may interfere with the diagnosis or evaluation of response to therapy, such as suspected or confirmed concurrent causes of vulvovaginitis and/or cervicitis (mixed infection)
• •2. Need for systemic and/or topical (vaginal) antifungal treatment, including prescription or over-the-counter products during the study and treatment for VVC 28 days prior to randomization
• •3. Subject is actively menstruating at the time of the Baseline visit.
• •4. Subject has uncontrolled diabetes mellitus.
• •5. Subject has a vaginal sample with pH \>4.5.
• •6. Subject has a history of or an active cervical/vaginal cancer.